karxt bristol myers squibb news - Search News

Bristol Myers Squibb Stock Rises

Seeking Alpha · 15h

Bristol-Myers Squibb: Unlocking Value With KarXT FDA Approval And Oncology Pipeline Progress

Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of Schizophrenia. See why BMY stock is a Buy.

MarketWatch on MSN · 18h

Bristol-Myers Squibb stock jumps on schizophrenia drug approval

Bristol-Myers Squibb shares rose in premarket trade on Friday after the Food and Drug Administration approved a schizophrenia drug.

Bristol Myers wins US FDA approval for new type of schizophrenia drug

The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the first new type of antipsychotic medicine in decades.

8h

Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential

Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. BMO Capital analyst notes ...

health.wusf.usf.edu2h

A new kind of drug for schizophrenia promises fewer side effects

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

FDA OKs First-in-Class Antipsychotic for Schizophrenia

The FDA has approved a first-in-class antipsychotic that targets cholinergic receptors without blocking dopamine receptors.

17h

Wall Street Breakfast Podcast: Bristol-Myers Wins FDA Nod For Novel Antipsychotic

Bristol-Myers wins FDA nod for novel antipsychotic. DirecTV, Dish close in on merger to form largest US pay-TV service: ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results